NDA 021870 · Feinstein
Fludeoxyglucose F18
Fludeoxyglucose F-18 · Intravenous · Radioactive Diagnostic Agent
Last checked: Nov 19, 2026Latest source record: Nov 9, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2005
Aug 19, 2005
Approved uses
1
Original approval plus efficacy supplements
Registered trials
389
27 Phase 3, 75 recruiting
FAERS reports
274
204 serious, 43 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 11, 2019.
Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F 18 Injection is indicated for positron emission tomography (PET) imaging in the following settings: Oncology: For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. Cardiology: For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. Neurology: For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures ( 1 ). 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function in patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging. 1.3 Neurology For the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 1.1 Oncology For assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 1.2 Cardiology For the identification of left ventricular...
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- FLUDEOXYGLUCOSE F18 · FLUDEOXYGLUCOSE F-18 20-400mCi/ML · INJECTABLE, INTRAVENOUS · Prescription · TE AP
- FLUDEOXYGLUCOSE F18 · FLUDEOXYGLUCOSE F-18 20-200mCi/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · INJECTABLE, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fludeoxyglucose F-18" as an intervention, any sponsor and status, largest first.
- Combination Chemotherapy in Treating Young Patients With Hodgkin's LymphomaPivotal-lookingCompleted
Christine Mauz-KörholzAcademic, hospital or other
NCT00433459 · 2,134 participants · Start Jan 2007 · Primary completion Jan 2013
Drug: cyclophosphamide; dacarbazine and 4 more · For: Lymphoma
Sites: Giessen, Germany; Edinburgh, United Kingdom
- Fludeoxyglucose F 18 PET Scan-Guided Therapy or Standard Therapy in Treating Patients With Previously Untreated Stage I or Stage II Hodgkin's LymphomaPivotal-lookingStatus unknown
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT00433433 · 1,952 participants · Start Oct 2006 · Primary completion Dec 2011
Drug: ABVD q4 weeks; BEACOPP escalated q3 weeks · For: Lymphoma
Sites: Nijmegen, Netherlands
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and NivolumabPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT05675410 · 1,875 participants (planned) · Start May 11, 2023 · Primary completion Apr 28, 2031
Drug: Bleomycin Sulfate; Brentuximab Vedotin and 11 more · For: Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 419 sites in all
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsPivotal-lookingRecruiting
Children's Oncology GroupResearch network
NCT04293562 · 1,400 participants (planned) · Start Jul 21, 2020 · Primary completion Jun 30, 2029
Drug: Asparaginase Erwinia chrysanthemi; Cytarabine and 9 more · For: Acute Myeloid Leukemia
Sites: Birmingham, Alabama; Mobile, Alabama; Mesa, Arizona · 206 sites in all
- Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin LymphomaPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00678327 · 1,202 participants · Start Aug 29, 2008 · Primary completion Jan 31, 2016
Drug: bleomycin sulfate; filgrastim and 9 more · For: Lymphoma
Sites: Southampton, United Kingdom
University of SaskatchewanAcademic, hospital or other
NCT02811185 · 1,012 participants · Start Jun 2016 · Primary completion Jan 2017
Drug: [F-18]-Fludeoxyglucose · For: Positron-Emission Tomography and Cone-Beam Computed Tomography
- Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity CancerPivotal-lookingRecruiting
NRG OncologyAcademic, hospital or other
NCT04333537 · 686 participants (planned) · Start Sep 23, 2020 · Primary completion Apr 27, 2031
Drug: Imaging Agent · For: Buccal Mucosa Squamous Cell Carcinoma; Floor of Mouth Squamous Cell Carcinoma; Gingival Squamous Cell Carcinoma and 9 more
Sites: Birmingham, Alabama; Gilbert, Arizona; Phoenix, Arizona · 107 sites in all
- Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ PatientsPivotal-lookingCompleted
The Lymphoma Academic Research OrganisationAcademic, hospital or other
NCT01285765 · 650 participants · Start Dec 2010 · Primary completion May 23, 2020
Drug: RCHOP21 · For: DLBCL
Sites: Antwerp, Belgium; Bruges, Belgium; Brussels, Belgium · 83 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- cytokine release syndrome24
- drug ineffective17
- nausea16
- off label use15
- hypotension13
- neutropenia13
- platelet count decreased12
- pyrexia12
- rash maculo-papular11
- bone marrow failure10
- death10
- wrong product administered10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2006 | 2 |
| 2009 | 9 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 14 |
| 2013 | 6 |
| 2016 | 3 |
| 2017 | 9 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 13 |
| 2021 | 18 |
| 2022 | 42 |
| 2023 | 51 |
| 2024 | 24 |
| 2025 | 36 |
| 2026 | 23 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 18F-Fludeoxyglucose PET/CT in SCLC: Analysis of the CONVERT Randomized Controlled Trial.
Manoharan P, Salem A, Mistry H, et al. · J Thorac Oncol 2019 · Clinical Trial, Phase III, Randomized Controlled Trial
- Unforeseen N2 Disease after Negative Endosonography Findings with or without Confirmatory Mediastinoscopy in Resectable Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Bousema JE, van Dorp M, Noyez VJJM, et al. · J Thorac Oncol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer.
Yokomise H, Gotoh M, Okamoto T, et al. · J Thorac Cardiovasc Surg 2007 · Randomized Controlled Trial
- Positron emission tomography measurement of cerebral metabolic correlates of yohimbine administration in combat-related posttraumatic stress disorder.
Bremner JD, Innis RB, Ng CK, et al. · Arch Gen Psychiatry 1997 · Clinical Trial, Randomized Controlled Trial
- Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis.
Deppen SA, Blume JD, Kensinger CD, et al. · JAMA 2014 · Meta-Analysis, Research Support, N.I.H., Extramural
- Increase in volume of ablation zones during follow-up is highly suggestive of ablation site recurrence in colorectal liver metastases treated with radiofrequency ablation.
Kele PG, de Jong KP, van der Jagt EJ · J Vasc Interv Radiol 2012 · Clinical Trial
Sponsor: Feinstein
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.